Clinical trials: Targeted Molecular Therapy
Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur…
- Conditions
- Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Rhabdoid Tumor of the Kidney, Stage I Wilms Tumor
- Trial name
- NCT01118078
- Testing
- DNA methylation analysis, gene expression analysis, microarray analysis
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898742
- Testing
- DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Brain Tumor, Brain Tumor, Recurrent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease.
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric
- Trial name
- NCT04023669
- Testing
- Prexasertib, Cyclophosphamide, Gemcitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Metastatic Solid Tumors (Any Localization)
Molecular Screening for Cancer Treatment Optimization
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival…
- Trial name
- MOSCATO 02 (NCT01566019)
- Testing
- Tumoral biopsy
- Where
- France
- Volunteers
- 2,150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hepatocellular Carcinoma, Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
- Trial name
- NCT01482520
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Chondrosarcomas, Cartilage Tumours
Diagnostic and Therapeutic Targets in Cartilaginous Tumours
This study, "Finding new diagnostic and therapeutic targets in cartilaginous tumours," focuses on improving the diagnosis, prognostic stratification, and treatment options for chondroid tumours, particularly chondrosarcoma.
- Trial name
- NCT07315542
- Testing
- Tumour tissue analysis, Molecular validation, Liquid biopsy analysis
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- St. Anne's University Hospital Brno, Czech Republic
Neoplasms, Therapy-Associated
The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer
Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer and explore some biomarkers that relate to target therapy.
- Trial name
- NCT02523495
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Huazhong University of Science and Technology
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Background: Medullary thyroid carcinoma (MTC) is common in people with a genetic disorder called multiple endocrine neoplasia (MEN).
- Conditions
- Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
- Trial name
- NCT00514046
- Testing
- Vandetanib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
- Trial name
- iNUDGE (NCT05853887)
- Testing
- iNUDGE
- Where
- 6 sites in United States
- Volunteers
- 260 people
- Sponsor
- Charu Aggarwal
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Pineoblastoma
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
Children, adolescents and young adults with relapsed or treatment refractory pineoblastoma (rPB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not available.
- Trial name
- NCT02596828
- Testing
- Temozolomide, Irinotecan, Dasatinib
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- University of Regensburg
Relapsed or Refractory Pediatric Tumor
Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling
In the light of the development of high-throughput technologies enabling a biology-based reclassification of tumors and the increasing number of available specifically targeting anticancer agents the era of "precision medicine"…
- Trial name
- MAPPYACTS (NCT02613962)
- Testing
- biopsy or surgical resection of tumor and blood sampling
- Where
- 5 sites in France, Ireland and 3 more
- Volunteers
- 791 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Leukemia
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896766
- Testing
- loss of heterozygosity analysis, microarray analysis, polymorphism analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Metastatic Renal Cell Carcinoma
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively.
- Trial name
- NCT05816642
- Testing
- sunitinib or pazopanib, PD-1 inhibitor combined with axitinib
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Cancer
Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients
This study will examine the effects of certain investigational anti-cancer drugs on the genetic and protein makeup of cells. The findings will be entered into a database that may be used to: 1) determine the optimal dose of drug…
- Trial name
- NCT00055380
- Testing
- Oral cytobrushing
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)